Phase II Examination of Irinotecan, Cetuximab and Everolimus to Chemotherapy Resistent Patients With Metastatic Colorectal Cancer and KRAS Mutations or After Progression With KRAS Wildtype on Irinotecan and Cetuximab - Effect and Biological Markers.

Trial Profile

Phase II Examination of Irinotecan, Cetuximab and Everolimus to Chemotherapy Resistent Patients With Metastatic Colorectal Cancer and KRAS Mutations or After Progression With KRAS Wildtype on Irinotecan and Cetuximab - Effect and Biological Markers.

Completed
Phase of Trial: Phase II

Latest Information Update: 07 Dec 2016

At a glance

  • Drugs Cetuximab (Primary) ; Everolimus; Irinotecan
  • Indications Colorectal cancer
  • Focus Biomarker; Pharmacogenomic; Therapeutic Use
  • Acronyms ICE
  • Most Recent Events

    • 19 Mar 2012 Actual end date (Mar 2012) added as reported by ClinicalTrials.gov.
    • 19 Mar 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 08 Jul 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top